Formulation of Nanomicelles to Improve the Solubility and the Oral Absorption of Silymarin by Piazzini, Vieri et al.
molecules
Article
Formulation of Nanomicelles to Improve the
Solubility and the Oral Absorption of Silymarin
Vieri Piazzini 1 , Mario D’Ambrosio 2, Cristina Luceri 2 , Lorenzo Cinci 2, Elisa Landucci 3,
Anna Rita Bilia 1 and Maria Camilla Bergonzi 1,*
1 Department of Chemistry, University of Florence, Via U. Schi↵ 6, 50019 Sesto Fiorentino, Florence, Italy;
vieri.piazzini@unifi.it (V.P.); ar.bilia@unifi.it (A.R.B.)
2 Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA),
Section of Pharmacology and Toxicology, University of Florence, Viale Pieraccini 6, 50139 Florence, Italy;
mario.dambrosio@unifi.it (M.D.); cristina.luceri@unifi.it (C.L.); lorenzo.cinci@unifi.it (L.C.)
3 Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence,
Viale Pieraccini 6, 50139 Florence, Italy; elisa.landucci@unifi.it
* Correspondence: mc.bergonzi@unifi.it; Tel.: +39-055-455-3678
Academic Editor: Dominique Delmas
Received: 10 April 2019; Accepted: 28 April 2019; Published: 30 April 2019
!"#!$%&'(!
!"#$%&'
Abstract: Two novel nanomicellar formulations were developed to improve the poor aqueous
solubility and the oral absorption of silymarin. Polymeric nanomicelles made of Soluplus and
mixed nanomicelles combining Soluplus with d-↵-tocopherol polyethylene glycol 1000 succinate
(vitamin E TPGS) were prepared using the thin film method. Physicochemical parameters were
investigated, in particular the average diameter, the homogeneity (expressed as polydispersity index),
the zeta potential, the morphology, the encapsulation e ciency, the drug loading, the critical micellar
concentration and the cloud point. The sizes of ~60 nm, the narrow size distribution (polydispersity
index 0.1) and the encapsulation e ciency >92% indicated the high a nity between silymarin and
the core of the nanomicelles. Solubility studies demonstrated that the solubility of silymarin increased
by ~6-fold when loaded into nanomicelles. Furthermore, the physical and chemical parameters of
SLM-loaded formulations stored at room temperature and in refrigerated conditions (4  C) were
monitored over three months. In vitro stability and release studies in media miming the physiological
conditionswere also performed. In addition, both formulations did not alter the antioxidant properties
of silymarin as evidenced by the 1,1-Diphenyl-2-picrylhydrazyl radical (DPPH) assay. The potential
of the nanomicelles to increase the intestinal absorption of silymarin was firstly investigated by the
parallel artificial membrane permeability assay. Subsequently, transport studies employing Caco-2
cell line demonstrated that mixed nanomicelles statistically enhanced the permeability of silymarin
compared to polymeric nanomicelles and unformulated extract. Finally, the uptake studies indicated
that both nanomicellar formulations entered into Caco-2 cells via energy-dependent mechanisms.
Keywords: silymarin; drug delivery; polymeric nanomicelles; mixed nanomicelles; antioxidant
activity; PAMPA; Caco-2 cell line; oral bioavailability
1. Introduction
Silymarin (SLM) is a mixture of flavonolignans (silybin A and silybin B, isosilybin A and isosilybin
B, silychristin A and silychristin B, isosilychristin A and isosilychristin B, silydianin, silymonin, cisilybin
A and cisilybin B, isocisilybin A and isocisilybin B, silandrin A and silandrin B, cisilandrin A and
cisilandrin B, isosilandrin A and isosilandrin B, isocisilandrin A and isocisilandrin B, silyhermin A and
silyhermin B, neosilyhermin A and neosilyhermin B), flavonoids (taxifolin and quercetin), fatty acids,
proteins, fixed oil, betaine and polyphenols extracted from fruits of Silybum marianum (L.) Gaertn.
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(asteraceae), also known as milk thistle [1]. Since SLM can induce the regeneration of hepatocytes, it
has been used since the ancient times in the treatment of liver and gallbladder diseases [2,3]. Moreover,
SLM has antioxidant and anti-inflammatory properties, and its e cacy in the treatment of metabolic
disorders in diabetes was reported, in particular with regard to lipid profile and blood glucose level [4],
cancer [5], neurological disorders [6], cardiac [7], gastrointestinal [8], lung [9], skin [10] and renal
diseases [11]. In addition, the benefits of SLM against radiotherapy-induced mucositis and hand-foot
syndrome in patients treated with capecitabine are well documented [12,13].
However, the aqueous solubility of SLM is poor, and it is usually administered in adult patients
in the form of capsules at a dosage of 240–800 mg/day [14,15]. Moreover, pharmacokinetic analysis
revealed that after oral administration to human healthy volunteers the main flavonolignans of SLM
(silybin A, silybin B, isosilybin A, isosilybin B, silychristin and silydianin) are metabolized to their
conjugates (sulfates and glucuronides) and rapidly eliminated with relatively short half-lives (1–3, 3–6,
and 3–5 h for the free, conjugated and total SLM flavonolignans, respectively) [16].
To overcome these drawbacks, in particular the low aqueous solubility and limited oral
bioavailability, several strategies were employed in recent years, including complexation with
phospholipids (phytosomes) [17], inclusion complex with  -cyclodextrins [18], solid dispersions [19],
microparticles [20], polymeric nanoparticles [21], liposomes [22], solid lipid nanoparticles [23],
nanostructured lipid carriers [24], micro-/nanoemulsions [25,26], self-microemulsifying drug delivery
systems [27] and polymeric micelles [28,29].
In the last few years, nanomicelles have gained increasing attention in the diagnosis and treatments
of many pathologies, culminated with the approval by the Food and Drug Administration (FDA) of
Genexol®PM, a micelle formulation of paclitaxel for the treatment of breast, ovarian and lung cancer
in 2007 [30]. Nanomicelles are generally made of amphiphilic polymers that self-assemble in water
into hydrophobic core-hydrophilic shell nanostructures (20–200 nm) at concentrations higher than
the critical micellar concentration (CMC). The presence of the lipophilic core increases the solubility
of poorly water-soluble molecules and o↵ers the possibility to obtain a controlled drug release [31],
while the hydrophilic shell protects the encapsulated drug from the external medium and prevents the
interaction with plasma components, resulting in long circulation properties in vivo. Moreover, the
small particle size prolongs the residence time in blood circulation, bypassing the liver and spleen
filtration and the glomerular elimination, and enhances cellular uptake and the ability to cross epithelial
barriers. All these aspects result in increased drug bioavailability [32].
Hereby, the aim of the present study was to investigate and compare polymeric nanomicelles
(PNM) andmixed nanomicelles (MNM) as oral dosage forms to enhance the solubility and the intestinal
absorption of SLM. Solupluswas employed as amphiphilic polymer for the development of PNM.Many
researchers reported its ability to improve the oral bioavailability of poorly water-soluble drugs [33,34].
In addition, it exerts inhibitory activity on P-glycoprotein (P-gp) e✏ux pumps [35]. In this regard,
considering that SLM is a P-gp substrate [36], MNMwere also developed combining Soluplus with
d-↵-tocopherol polyethylene glycol 1000 succinate, also known as vitamin E TPGS (TPGS). TPGS is
widely employed in the food and drug industry as an emulsifier, stabilizer, solubilizer and permeation
enhancer. In addition, TPGS has been used to enhance the stability of nano-drug delivery systems [37]
and to inhibit the P-gp-mediated e✏ux enhancing the drug absorption in the intestinal lumen [38].
To the best of our knowledge, there are no reports in which SLM was formulated into Soluplus and
Soluplus/TPGS nanomicelles, and for the first time the influence of these excipients on SLM permeation
and P-gp-mediated e✏ux in Caco-2 cell line was studied. Empty and SLM-loaded PNM and MNM
were chemically and physically characterized in terms of size, homogeneity, zeta potential, morphology,
CMC, cloud point, encapsulation e ciency, loading capacity and storage stability. Moreover, the
antioxidant properties of unformulated SLM and SLM-loaded nanomicelles were compared. In vitro
stability studies in simulated gastrointestinal environment and blood conditions were performed. The
ability of PMN and MNM to improve the passive permeation of SLM was first evaluated by using the
Parallel Artificial Membrane Permeability Assay (PAMPA), then by employing the Caco-2 cells.
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2. Results and Discussion
2.1. Preparation and Characterization of Nanomicelles
In this work, the thin film method was used to prepare nanomicelles formulations [39]. Since a
low CMC value indicates a high resistance of nanomicelles against dilution by body fluids [40], the
total polymer concentration (5% w/v) was selected above the CMC value of the surfactant(s). Soluplus
consists of polyvinyl caprolactam (57%), polyvinyl acetate (30%) and polyethylene glycol (13%). It has
a very low CMC value (7.6 mg/L) that confers stability to micellar formulations upon dilution in vivo,
and it is considered a safe excipient since no adverse e↵ects were observed in animals at a dose of
1000 mg/Kg [33–35]. TPGS is a PEGylated vitamin E with amphiphilic properties and a relatively low
CMC (0.02% w/w). Furthermore, it is recognized by the FDA as a safe pharmaceutic excipient [37].
SLM-PNM were prepared testing increasing amounts of extract powder, from 0.5 mg/mL to 4 mg/mL.
PNM loaded with 0.5, 1, 2, 3 mg/mL of SLM had similar average diameter and homogeneity to the
empty PNM, while in presence of 4 mg/mL of the extract, the PNM were larger (>200 nm) and highly
polydispersed (Polydispersity Index, PdI > 0.3). Thus, 3 mg/mL (corresponding to 1.63 mg/mL of SLM)
was selected as the optimal extract concentration (Table 1).
Table 1. Physical and chemical characterization of empty, SLM- and fluorescein isothiocyanate
(FITC)-loaded PNM and MNM (Mean ± SD, n = 3).
Sample AverageDiameter (nm) PdI
Zeta Potential
(mV) EE% LC%
PNM 59.7 ± 0.1 0.06 ± 0.02  5.5 ± 0.6 - -
MNM 60.2 ± 2.5 0.05 ± 0.01  4.7 ± 0.6 - -
SLM-PNM 61.3 ± 6.0 0.10 ± 0.03  4.7 ± 0.5 93.0 ± 3.9 2.9 ± 0.2
SLM-MNM 61.5 ± 4.3 0.10 ± 0.03  4.3 ± 0.5 92.9 ± 5.3 2.9 ± 0.2
FITC-PNM 60.6 ± 2.1 0.05 ± 0.01  6.2 ± 0.3 95.3 ± 1.2 1.9 ± 0.1
FITC-MNM 63.3 ± 1.4 0.10 ± 0.01  5.9 ± 0.2 95.7 ± 1.2 1.9 ± 0.0
PNM: Polymeric nanomicelles; MNM: Mixed nanomicelles; SLM-PNM: Silymarin-loaded polymeric nanomicelles;
SLM-MNM: Silymarin-loaded mixed nanomicelles; FITC-PNM: Fluorescein isothiocyanate polymeric nanomicelles;
FITC-MNM: Fluorescein isothiocyanate mixed nanomicelles.
For the optimization of SLM-MNM, di↵erent Soluplus/TPGS gravimetric ratios were tested (from
20:1 to 2:1). As the concentration of TPGS increased, the average diameter and the PdI of SLM-MNM
increased correspondingly. Since an average hydrodynamic diameter below 100 nm can increase the
intestinal drug absorption of nanomicelles after oral administration [33], only SLM-MNM obtained
with Soluplus/TPGS 20:1 showed the appropriate technological parameters (Table 1).
Empty PNM and MNM had a light-blue appearance, while SLM-loaded formulations were
transparent with a light-yellow opalescence (Figure 1).
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The calculated CMC values of PNM and MNM were 0.3 × 10−3 mM and 1.5 × 10−3 mM, 
respectively. By increasing the concentration of TPGS, the CMC value of the system increased. Thus, 
according to the average diameter and PdI, the ratio of 20:1 Soluplus/TPGS was chosen as the best 
formulation. The CMC value of the micellar formulations is a crucial parameter because low CMC 
values ensure stability, resistance against dissociation and prevent the loss of the encapsulated drug 
during the dilution by the body fluids [41]. In general, a CMC value less than 135 mg/L is considered 
enough to resist toward dissociation upon dilution after oral administration [40]. The low CMC of 
the developed PNM and MNM can be attributed to the presence of highly lipophilic regions of the 
polymers employed. 
Fluorescent PNM and MNM were prepared for in vitro uptake studies adding fluorescein 
isothiocyanate (FITC) instead of SLM and using the same amounts of Soluplus (for PNM) and 
Soluplus/TPGS (for MNM) described for empty formulations and SLM-loaded nanomicelles. The 
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mixed nanomicelles (MNM); (C) Silymarin (SLM)-loaded PNM; (D) SLM-loaded MNM; (E) SLM
aqueous suspension.
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The calculatedCMCvalues of PNMandMNMwere 0.3⇥ 10 3 mMand 1.5⇥ 10 3 mM, respectively.
By increasing the concentration of TPGS, the CMC value of the system increased. Thus, according to
the average diameter and PdI, the ratio of 20:1 Soluplus/TPGS was chosen as the best formulation. The
CMC value of the micellar formulations is a crucial parameter because low CMC values ensure stability,
resistance against dissociation and prevent the loss of the encapsulated drug during the dilution by the
body fluids [41]. In general, a CMC value less than 135 mg/L is considered enough to resist toward
dissociation upon dilution after oral administration [40]. The low CMC of the developed PNM and
MNM can be attributed to the presence of highly lipophilic regions of the polymers employed.
Fluorescent PNM and MNM were prepared for in vitro uptake studies adding fluorescein
isothiocyanate (FITC) instead of SLM and using the same amounts of Soluplus (for PNM) and
Soluplus/TPGS (for MNM) described for empty formulations and SLM-loaded nanomicelles. The
results are reported in Table 1. FITC-loaded nanomicelles had an intense yellow-green color (Figure 2).
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2.2. Solubilization Capacity Determination
The solubilization apacity of PNM and MNMwas invest gated adding an excess of SLM to each
micellar formulation. To investigate the e↵ect of TPGS on SLM solubilit , di↵erent gravimetric ratio
between Soluplus and TPGS were employed to prepare MNM (Table 2).
Table 2. SLM solubil ty and solubility factor in P ,MNMandwater t room temp rature ( ean± SD,
n = 3).
Sample SLM Solubility (mg/mL) Sf
Soluplus 2.41 ± 0.03 6.51
Soluplus/TPGS 20:1 2.05 ± 0.07 5.54
Soluplus/TPGS 10:1 1.89 ± 0.01 5.11
Soluplus/TPGS 5:1 1.83 ± 0.04 4.95
Soluplus/TPGS 4:1 1.78 ± 0.04 4.81
Soluplus/TPGS 3:1 1.64 ± 0.04 4.43
Soluplus/TPGS 2:1 1.58 ± 0.04 4.27
Water 0.37 ± 0.01 -
SLM: Silymarin; Sf: Solubility factor.
As reported in Table 2, all micellar formulations increased the solubility of SLM compared with
the aqueous solubility. Soluplus PNM determined the highest improvement of water solubility of
the extract (more than 6-fold). The Sf for MNMwas lower than PNM, in particular with increasing
concentrations of TPGS. This fact might be attributed to the presence of TPGS, which is characterized
by a smaller lipophilic portion compared to Soluplus [45]. Thus, these results evidenced that Soluplus
played a key role in increasing the solubility of SLM, and the optimal Soluplus/TPGS ratio for MNM
was 20:1, according to the physical characterization.
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2.3. Cloud Point
The cloud point is the temperature at which a homogenous solution of amphiphilic polymers
presents a cloudy appearance [46]. The increase in temperature causes the dehydration of the
hydrophilic chain of the polymers, resulting in micelles aggregation and loss of the stability of the
nanosystem. The determination of the cloud point helps to select the storage conditions and to predict
the stability of the formulation after administration. The cloud point of SLM-PNM and SLM-MNMwas
investigated. SLM-PNM exhibited a cloud point of 40.7 ± 0.8  C (Mean ± SD, n = 3), while SLM-MNM
of 38.2 ± 1.5  C (Mean ± SD, n = 3). The slight decrease of cloud point for SLM-MNMmight be due
to the penetration of TPGS in the core of the nanomicelles that causes water expulsion, resulting in
increased hydrophobic interactions [44,45].
2.4. Stability Studies
2.4.1. Storage Stability
The chemical and physical storage stability of nanomicelles was monitored over three months both
in refrigerated conditions (4  C) and at room temperature. The physical parameters were evaluated by
light scattering analyses, the EE%was determined by HPLC, while the presence of any SLM precipitate
was visually checked.
As shown in Tables 3 and 4, both SLM-PNM and SLM-MNM were stable. The physical and
chemical parameters before and after storage were substantially comparable. Moreover, no SLM
precipitates were observed in all samples. These results are interesting, since it is reported that micellar
formulations composed with di↵erent Soluplus/TPGS ratios compared to those proposed in the present
work are not stable during the storage for a long time [47].
Table 3. Storage stability test of SLM-PNM and SLM-MNM at 4  C (Mean ± SD, n = 3).





SLM-PNM 57.5 ± 0.5 0.07 ± 0.01  4.3 ± 0.2 93.2 ± 0.1 NO
SLM-MNM 59.7 ± 0.1 0.04 ± 0.01  4.5 ± 0.5 92.7 ± 0.1 NO
SLM-PNM: Silymarin-loaded polymeric nanomicelles; SLM-MNM: Silymarin-loaded mixed nanomicelles; PdI:
polydispersity index; EE%: encapsulation e ciency.
Table 4. Storage stability test of SLM-PNM and SLM-MNM at room temperature (Mean ± SD, n = 3).





SLM-PNM 56.7 ± 0.2 0.06 ± 0.01  4.4 ± 0.2 92.7 ± 0.1 NO
SLM-MNM 57.8 ± 0.2 0.06 ± 0.01  4.7 ± 0.4 92.8 ± 0.1 NO
SLM-PNM: silymarin-loaded polymeric nanomicelles; SLM-MNM: silymarin-loaded mixed nanomicelles; PdI:
polydispersity index; EE%: encapsulation e ciency.
2.4.2. Gastrointestinal Stability
The main obstacle for oral drug delivery is the harsh environment of the gastrointestinal tract.
The dissociation of the nanomicelles in the stomach and/or in the intestine causes the release of
the encapsulated drug. On the other hand, particle size plays a key role in the gastrointestinal
absorption, and it is reported that an average diameter less than 300 nm is advantageous for intestinal
permeation [48]. To simulate the gastrointestinal conditions, SLM-PNMand SLM-MNMwere incubated
at 37  C in simulated gastric fluid (GF) followed by simulated intestinal fluid (IF).
As shown in Table 5, the average diameter of both formulations was comparable to that measured
before the experiment (Table 1), indicating that neither low pH value nor digestive enzymes influence
the stability of the developed nanomicelles. This could be due to the steric stabilization e↵ect of the
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PEG chains of the polymers [49]. Moreover, no SLM precipitation was found, confirming the stability
of both the formulations. Based on these results, it is conceivable that SLM could be absorbed at the
gastrointestinal level without the degradation of the carrier.
Table 5. Physical stability of SLM-loaded nanomicelles in simulated gastric fluid (GF) and simulated
intestinal fluid (IF) (Mean ± SD, n = 3).
GF IF
Sample Average Diameter(nm) PdI
Average Diameter
(nm) PdI
SLM-PNM 58.7 ± 1.1 0.12 ± 0.01 65.4 ± 2.2 0.20 ± 0.02
SLM-MNM 61.3 ± 0.8 0.11 ± 0.01 65.3 ± 1.4 0.13 ± 0.01
SLM-PNM: silymarin-loaded polymeric nanomicelles; SLM-MNM: silymarin-loaded mixed nanomicelles;
GF: simulated gastric fluid; IF: simulated intestinal fluid; PdI: polydispersity index.
2.4.3. Stability in Blood Conditions
After assessing the physical stability of nanomicelles in gastrointestinal conditions, the
formulations were incubated in phosphate bu↵er saline (PBS, pH 7.4) without and in presence
of human serum albumin (HSA, 45 g/L) at 37  C for 72 h to simulate the blood circulation.
The data reported in Table 6 suggest that both formulations were unchanged in PBS and in PBS
with HSA over a period of 72 h. The slight increase of the PdI after incubation in PBS with HSA
might be due to the coexistence of albumin and nanomicelles. The maximal increase of the sizes was
about 10–15 nm, therefore, the nanomicelles are able to maintain their structure in physiological pH
conditions and also in the presence of plasma proteins.
Table 6. Physical stability of SLM-loaded nanomicelles in phosphate bu↵er saline (PBS) without and
with HSA (Mean ± SD, n = 3).
SLM-PNM SLM-MNM
Medium Average Diameter(nm) PdI
Average Diameter
(nm) PdI
PBS 24 h 68.0 ± 1.1 0.08 ± 0.01 69.7 ± 3.4 0.07 ± 0.01
PBS 48 h 64.1 ± 1.8 0.12 ± 0.02 75.8 ± 4.4 0.08 ± 0.03
PBS 72 h 66.6 ± 1.2 0.09 ± 0.01 72.0 ± 1.4 0.11 ± 0.01
PBS + HSA 24 h 69.6 ± 1.3 0.21 ± 0.02 75.6 ± 6.3 0.26 ± 0.01
PBS + HSA 48 h 70.6 ± 0.4 0.24 ± 0.01 74.0 ± 2.1 0.24 ± 0.01
PBS + HSA 72 h 70.9 ± 0.2 0.25 ± 0.01 70.2 ± 1.1 0.25 ± 0.01
SLM-PNM: silymarin-loaded polymeric nanomicelles; SLM-MNM: silymarin-loaded mixed nanomicelles; PBS:
phosphate bu↵er saline; HSA: human serum albumin; PdI: polydispersity index.
2.5. In Vitro Release Studies
To confirm the hypothesis that SLM-PNM and SLM-MNM are stable in the gastrointestinal
tract and blood conditions, the release of SLM was monitored in di↵erent pH conditions comparing
SLM-loaded nanomicelles and an SLM ethanolic solution. Each medium was supplemented with
Tween 80 (0.5% w/v) to obtain sink conditions [50]. After 2 h in GF, 42.4% ± 0.5 of free-SLM in ethanol
was released, 85.7% ± 1.1 of free-SLM was released in IF within 6 h, in PBS more than 80% of SLM was
released within 4 h and after 10 h the percentage reached 100%. In the case of the micellar formulations,
no SLM was released in GF and IF, confirming that the PEG chains in the shell of the micelles protect
the core containing SLM from the gastric acid and intestinal fluids. This represents a promising result
because we can assert that nanomicelles avoid the SLM degradation in the gastrointestinal tract and
could improve the bioavailability of the extract. After 72 h in PBS, the cumulative release of SLM
from PNM and MNMwas only 3.2 ± 0.1% and 3.4 ± 0.2%, respectively, indicating that TPGS did not
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influence the release properties of the nanomicelles. The slow release of SLM observed for PNM and
MNMmight be due to the strong hydrophobic interaction between the extract and the inner core of the
nanomicelles. Thus, both PNM and MNM are able to extend the residence time of SLM in vivo. At the
end of the experiments, the samples in the dialysis bags were analyzed by DLS to assess the physical
stability of SLM-PNM and SLM-MNM.
2.6. Parallel Artificial Membrane Permeability Assay (PAMPA)
The Parallel Artificial Membrane Permeability Assay (PAMPA) permits the fast in vitro
determination of the ability of a compound to permeate artificial membranes by passive di↵usion
and therefore to estimate the gastrointestinal absorption after oral administration [51]. PAMPA gives
information not only on the permeability of single molecules, but also on the behavior of the extracts,
and recently the test was introduced to study formulated drugs [24,26,52–55]. In this work, PAMPA
was used to evaluate to e↵ect of nanomicelles on SLM permeability.
The results displayed in Figure 4 indicate that both PNM and MNM increased the e↵ective
permeability (Pe) of SLM. Statistical analysis confirmed a significant improvement of permeability
coe cient of SLM when formulated into MNM (** p < 0.01 vs. free-SLM) and, borderline, into PNM
(p = 0.069; Kruskal–Wallis test and Dunn’s multiple comparisons test). The increase in SLM permeation
when formulated into the nanomicelles is attributable to the increased lipophilicity of the extract [56].
Mass balance was higher than 80% for all the experiments, indicating that the calculated Pe is useful
for in vitro prediction [57].
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Figure 4. E↵ective per eability (Pe) of free-sily arin (Free-SL ), sily arin-loaded poly eric
nano icelles (SLM-PNM) and silymarin-loaded mixed nanomicelles (SLM-MNM). Data are expressed
as mean ± SD, n = 3. ** p < 0.01 vs. free silymarin, by Kruskal-Wallis test and Dunn’s lti le
c ris s t st.
However, PAMPA lacks pore-mediated permeability and transporters, so it is not suitable to
evaluate the influence of TPGS on P-gp mediated e✏ux on SLM. For this reason, permeation studies
with a biological layer based on Caco-2 cells were also performed.
2.7. Caco-2 Experiments
The Caco-2 cell line is considered a viable model to estimate human intestinal absorption [55].
In the present work, the e↵ect of the di↵erent dilutions (from 2-times to 100-times) of nanomicelles on
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the cell viability was investigated during 24 h to select the optimal concentration and time of exposure
for transport experiments. Both formulations showed very low cytotoxicity after 12 h of exposure at
the tested concentrations, proven by a cell viability value of >80%. In addition, the Lucifer yellow
passage was less than 3%, indicating the integrity of the layer [24]. However, a notable reduction of the
cell viability (>50%) compared to untreated control cells was evidenced after 24 h of incubation with
formulations diluted 2-times. Thus, considering that a cell viability  80% is required for acceptable
in vitro estimation and to allow the detection of the permeated SLM by HPLC-DAD analyses, both
formulations were diluted two times and the duration of the transport experiments was set to 12 h.
Since SLM is a substrate of P-gp [36], the absorption (AP-BL) and e✏ux (BL-AP) of SLM were
investigated adding SLM-PNM, SLM-MNM and free-SLM to the Transwell upper chamber (AP) for
the absorption study and to the lower chamber (BL) for the e✏ux study (Table 7).
Table 7. Apparent permeability coe cients (Papp) of free-SLM and SLM-loaded nanomicelles.
(Mean ± SD, n = 3).





SLM-PNM 9.10 ± 0.14 6.11 ± 1.25 0.67 ± 0.15
SLM-MNM 140.90 ± 15.06 * 6.16 ± 1.75 0.04 ± 0.01 *
Free-SLM N.D. 17.29 ± 0.30 N.A.
SLM-PNM: Silymarin-loaded polymeric nanomicelles; SLM-MNM: Silymarin-loadedmixed nanomicelles; Free-SLM:
Silymarin aqueous solution; N.D.: Not detected; N.A.: Not applicable. * p< 0.05 vs. SLM-PNMbyMannWhitney test.
The expression of P-gp gene in our Caco-2 cells was verified by RT-PCR. As shown in Figure 5, the
cells used in the present experiment showed expression levels comparable to that of positive control
(HCT-8 cancer cell line) [58].
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MNM had a significant higher apparent permeability (Papp) compared with PNM in AP-BL
experiments. Meanwhile, free-SLM was not detected into the basolateral chamber. These results
are attributable to the presence of TPGS, which increases not only the solubility of SLM but also its
permeation across the intestinal epithelium, amplifying the e↵ect of Soluplus [38]. To investigate the
influence of Soluplus and TPGS on P-gp e✏ux, the secretory permeability studies were also performed.
In this case, the Papp value of free SLM was ~6-fold higher compared with SLM-PNM and SLM-MNM,
suggesting that ATP-dependent intestinal transporters, such as the P-gp proteins, mediate the e✏ux
of SLM and that nanomicelles have a significa t inhibitory e↵ect on these transp rters. Moreover,
the e✏ux ratio for SLM- NM was significantly lower compared to SLM-PNM, indicating that the
combination of Soluplus and TPGS might play a synergistic e↵ect in the intestinal absorption of SLM.
These results confirmed that the developed MNM represent a promising approach for optimizing the
performance of nanomicelles as drug delivery systems.
The mechanisms involved in the internalization of PNM and MNMwere explored by performing
uptake experiments in the presence of an energy depletion agent (sodium azide), a clathrin-dependent
endocytosis inhibitor (chlorpromazine) or a caveolin-dependent endocytosis inhibitor (indomethacin)
or by setting the temperature at 4  C to inhibit active uptake processes [24]. These studies were
performed for 1 h, since the blocking of one uptake pathway may result in activation of other endocytic
mechanisms, which might confound the interpretation of the data [59].
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As evidenced in Figure 6, the cellular uptake of both FITC-PNM and FITC-MNM was statistically
inhibited at 4  C (** p < 0.01 vs. 37  C by Kruskal-Wallis test) and in the presence of sodium azide only
for the MNM formulation (* p < 0.05 vs. 37  C by Kruskal-Wallis test). Meanwhile, the presence of
indomethacin or chlorpromazine slightly a↵ected the internalization of FITC-loaded nanomicelles.
These data suggested that both formulations entered into Caco-2 cells via energy-dependent
mechanisms, in agreement with previously published data with similar formulations [47].
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2.8. DPPH Assay
The antioxidant activity plays a key role in SL therapeutic properties [2,3]. In this work, the
DPPH radical scavenging activity of free-SLM, SLM-loaded nanomicelles and empty formulations was
determined to investigate the e↵ect of PNM and MNM on the antioxidant properties of SLM.
As reported in Figure 7, SL showed a strong antioxidant activity, since the DPPH radical
scavenging activity was ~90%. oreover, it is possible to note that both nano icellar for ulations
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did not reduce the DPPH inhibition property of the extract. In particular, SLM loading into MNM
determined a slight increase in the percentage of the radical scavenging activity. This might be due
to the presence of TPGS in MNM, which is characterized by a moderate antioxidant activity [60,61],
as also confirmed by di↵erent antioxidant properties of the empty nanomicelles.Molecules 2019, 24, x FOR PEER REVIEW 11 of 20 
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3. Materials and Methods
3.1. Materials
Silymarin powder (SLM,  30% silybin (silybin A + silybin B) was obtained from Sigma Aldrich
(https://www.sigmaaldrich.com/catalog/DataSheetPage.do?brandKey=SIGMA&symbol=S0292). The
other compounds identified were the flavonolignans silychristin, silydianin, isosilybin A and isosilybin
B and the flavanonol taxifolin. The extract title was 54.3% according to our previous work [24]),
d-↵-Tocopherol polyethylene glycol 1000 succinate (TPGS), silibinin ( 98%, HPLC), fluorescein
5(6)-isothiocyanate (FITC,  90%, HPLC), pepsin, bile salts, pancreatic lipase, pancreatin, phosphate
bu↵ered saline BioPerformance Certified pH 7.4 (PBS), Tween®80, lecithin ( 99%, TLC) lyophilized
powder, cholesterol BioReagent ( 99%), 1,1-Diphenyl-2-picrylhydrazyl radical (DPPH), human serum
albumin ( 96%, HSA) lyophilized powder and all analytical grade and HPLC grade solvents were
obtained from Sigma Aldrich (Saint Louis, MO, USA) with the support of Sigma Aldrich Italia (Milan,
Italy). Soluplus® was a gift from BASF (Ludwigshafen, Germany) with the support of BASF Italia, BTC
Chemical Distribution Unit (Cesano Maderno, Monza e Brianza, Italy). Distilled water was obtained
from a Simplicity®UVWater Purification System, Merck Millipore (Darmstadt, Germany).
3.2. Methods
. .1. Nanomicelles Fabrication
SLM-PNM and SLM-MNMwere prepared by the thin film method [39]. Appropriate amounts of
Soluplus, TPGS (only for MNM) and SLM were dissolved in 20 mL MeOH/CH2Cl2 mixture (80:20 v/v).
Then, the solvents were evaporated at 30  C by a rotary evaporator for 30 min until the formation of
a thin film. Finally, the film was hydrated with 5 mL of distilled water under sonication for 5 min
followed by 20 min of magnetic stirring at 300 rpm.
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Empty PNM and MNM were prepared by the same method. Fluorescent formulations were
obtained adding FITC instead of SLM. The total polymer concentration for both PNM and MNMwas
5% w/v. The composition of the developed formulations is reported in Table 8.
Table 8. Nanomicelles composition.
Sample Soluplus (mg) TPGS (mg) SLM (mg) FITC (mg)
PNM 250 - - -
MNM 238 12 - -
SLM-PNM 250 - 15 -
SLM-MNM 238 12 15 -
FITC-PNM 250 - - 5
FITC-MNM 238 12 - 5
PNM: Polymeric nanomicelles; MNM: Mixed nanomicelles; SLM-PNM: Silymarin-loaded polymeric nanomicelles;
SLM-MNM: Silymarin-loaded mixed nanomicelles; FITC-PNM: Fluorescein isothiocyanate polymeric nanomicelles;
FITC-MNM: Fluorescein isothiocyanate mixed nanomicelles.
3.2.2. Theoretical Critical Micellar Concentration (CMC)
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where Smic is the solubility of SLM in each micellar formulation and Sw is the water solubility of
the extract. SLM analyses were performed, employing an HP 1100 Liquid Chromatograph (Agilent
Technologies, Santa Clara, CA, USA) equipped with a UV detector and a Luna Omega Polar (150 mm
⇥ 3 mm, 5 µm) (all from Agilent Technologies) RP-C18 analytical column. The software was HP 9000
(Agilent Technologies). SLM detection was at a wavelength of 288 nm. The mobile phase consisted of:
(A) formic acid/water pH 3.2, (B) acetonitrile and (C) methanol. The following gradient profile was
applied: 0–2 min 10% B and 10% C, 2–6 min 15% B and 22% C, 6–11 min 20% B and 30% C, 11–16 min
30% B and 40% C, 16–18 min 30% B and 40% C, 18–20 min 40% B and 40% C, 20–23 min 40% B and 40%
C, 23–27 min 10% B and 10% C. The flow rate was 0.5 mL/min. The calibration curve was prepared
using standard silibinin dissolved in methanol from a concentration range of 0.001–0.100 µg/µL, and
the concentration absorption relationship was above 0.999.
3.2.4. Nanomicelles’ Physical and Morphological Characterization
The average hydrodynamic diameter and the size distribution of nanomicelles (polydispersity
index, PdI) were determined by dynamic light scattering (DLS, Zsizer Nanoseries ZS90, Malvern
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Instrument, Worcestershire, UK) at 25  C and at a scattering angle of 90 . The zeta potential was
evaluated measuring the electrophoretic mobility of nanomicelles by electrophoretic light scattering
technique (ELS) employing the same instrument. The results were expressed as the average of
three measurements.
The morphology of PNM and MNM was investigated by means of transmission electron
microscopy (TEM, Jeol 1010, Tokyo, Japan). Before the analyses, the samples were placed onto
a 200-mesh copper grid coated with carbon and negative stained with 1% w/v phosphotungstic acid
solution (Electron Microscopy Sciences, Hatfield, PA, USA) [64].
3.2.5. Drug Loading and Encapsulation E ciency
The drug loading (DL%) and encapsulation e ciency (EE%) were determined by membrane
filtration method [65]. SLM-PNM, SLM-MNM, FITC-PNM and FITC-MNM were filtered with a
0.45 µm filter membrane. Non-encapsulated SLM (or FITC) was retained on the membrane, while
20 µL of the filtrate was disrupted with 980 µL of MeOH. The amount of SLM (or FITC) encapsulated
and loaded in the nanomicelles was quantified by HPLC. SLM analyses were carried out as described
above, FITC was quantified employing the same instrument and apparatus, while the mobile phase
consisted of (A) formic acid/water pH 3.2 and (B) acetonitrile. The flow rate was set at 0.5 mL/min.
The gradient profile was: 0–2 min 20% B, 2–22 min 20–85% B, 22–25 min 85–100% B, 25–28 min 20% B.
FITC chromatograms were acquired at a wavelength of 224 nm. For the calibration curve, di↵erent
concentrations ranging from 0.002 µg/µL to 0.057 µg/µL were used. The linear correlation coe cient
was >0.999.
The DL% and EE% were calculated by following equations:
DL% =
Weight o f SLM (or FITC) in nanomicelles
Weight o f SLM (or FITC) f ed +Weight o f the excipients
⇥ 100 (3)
EE% =
Weight o f SLM (or FITC)in nanomicelles
Weight o f SLM (or FITC) f ed
⇥ 100 (4)
All samples were analyzed in triplicate.
3.2.6. Cloud Point
The cloud point value of SLM-PNM and SLM-MNMwas determined by immersing glass tubes
containing 4 mL of micellar formulations in a water bath at room temperature. Then, the temperature
was increased until the appearance of the samples changed from clear to turbid. After that, the micellar
formulations were cooled down, and the measurements were replicated to obtain a triplicate [44,66].
3.2.7. Stability Studies
Storage Stability Studies
To investigate the physical and chemical stability of SLM-PNM and SLM-MNM, the samples
were transferred into glass bottles sealed with plastic caps and stored both at room temperature and
4  C over a period of three months. The average diameter, PdI, zeta potential, EE% and any SLM
precipitation phenomena were evaluated.
Gastrointestinal Stability Studies
The physical stability of SLM-loaded nanomicelles was evaluated after incubation of formulations
in simulated gastric fluid (GF) followed by simulated intestinal fluid (IF). GF consisted of 2 g of NaCl,
3.2 g of pepsin and 7 mL of HCl diluted to 1 L. The pH value was adjusted to 1.2 with HCl 1 N.
SLM-PNM and SLM-MNMwere mixed with GF (final ratio 1:1 v/v) and maintained at 37  C under
continuous shaking (250 rpm) for 2 h. Then, the digested samples were incubated for 6 h at 37  C with
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IF. IF consisted of pancreatic lipase (4.8 mg/mL), bile salts (5 mg/mL), pancreatin (0.5 mg/mL) and
CaCl2 750 mM. The pH value was adjusted to 7.0 with NaOH 1 N. After the incubation both in GF and
IF, the average diameter and PdI were evaluated [53,67]. The studies were performed in triplicate.
Stability in Blood Conditions
The average diameter and size distribution of SLM-PNM and SLM-MNMwere evaluated after
72 h of incubation in PBS (pH 7.4) in the absence or in the presence of human serum albumin at a
physiological concentration (HSA, 45 mg/mL). The samples were diluted into the media to obtain a
polymer concentration of 0.5 mg/mL, then were incubated for 72 h at 37  C under shaking (250 rpm). At
scheduled time points (24 h, 48 h, 72 h), aliquots of the samples were collected for DLS analyses [68,69].
The assays were performed in triplicate.
3.2.8. In Vitro Release Studies
SLM release from PNM and MNM was studied by the dialysis bag method. In brief, 2 mL
of SLM-PNM, SLM-MNM and SLM solution with equivalent SLM concentration were added to a
regenerated cellulose dialysis membrane (Spectrum Laboratories, Inc., Breda, The Netherlands, MWCO
12–14 kD) and then immersed in 200 mL of the release media at 37  C under magnetic stirring at
100 rpm. Enzyme-free GF, IF and PBS with 0.5% Tween 80 were selected as release media. SLM release
in GF was monitored during 2 h, in IF over a period of 6 h, while in PBS during 72 h. At predetermined
time intervals, 1 mL of release medium was withdrawn for HPLC analyses and replaced with the same
volume of fresh release medium. All experiments were performed in triplicate.
3.2.9. PAMPA Studies
PAMPAwas carried out on 96-well filter plates (Millipore, Billerica, MA, USA). A lecithin (1% w/v)
and cholesterol (0.8% w/v) solution in 1,7-octadiene was prepared as artificial membrane. Then,
10 µL of this solution was added on the PVDF membrane filters in the donor compartments. After
the application of the artificial membrane, 0.25 mL of SLM-PNM, SLM-MNM and SLM solution
was added to each well of the donor compartment, and 0.25 mL of 5% DMSO solution in PBS was
added to each well acceptor compartment. Then, after placing the donor compartment into the
acceptor compartment, the system was transferred into a sealed container and incubated at room
temperature for 2 h. After the incubation, SLM concentration in the donor and acceptor compartment
















where A is the active surface area, VD and VA the well volume of the donor and acceptor plate,
respectively, t the incubation time (s), CAt and CDt the concentration of SLM in the acceptor and donor
plate at time t, respectively. Ceq was calculated according to:
Ceq =
[CDt ⇥VD + CAt ⇥VA]
VA +VD
(6)
Mass balance was also calculated. The assay was performed in triplicate.
3.2.10. Caco-2 Cell Lines
The colorectal adenocarcinoma cell line (Caco-2) was purchased from American Tissue Type
Culture Collection (Manassas, VA, USA) and cultured in Dulbecco’s modified Eagle’s medium (Thermo
Fisher Scientific, Rodano, Milan, Italy) with 20% fetal bovine serum (FBS) (Thermo Fisher Scientific,
Rodano, Milan, Italy), 100 U/
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Italy) in 5% CO2 at 37  C. An MTS assay was used to determine the cell viability after exposure to of
MNM, PNM, SLM-MNM and SLM-PNM or to free-SLM for 12 h [70]. The relative cell viability was
expressed as a percentage of the untreated control group.
Transport Studies
Caco-2 cells were seeded into 12-well PET Transwell plates (1.13 cm2 growth surface area and pore
size 0.4 µm, Greiner Bio-One, Milan, Italy) at a density of 2⇥ 105 cells/cm2 and grown for 21 days to form
a confluent monolayer. Before the transport studies, the integrity of the cellular barrier was assessed
using Lucifer yellow (LY) permeability test [56]. Absorptive (AP-BL) and secretive (BL-AP) transport
experiments in the Caco-2 cell monolayer were performed by incubating SLM-MNM, SLM-PNM
(diluted 2 times) and SLM aqueous solution for 12 h in the apical or in the basal compartment. Samples
of media collected from the basal or apical compartment were used to detect SLM by HPLC. The





where VA is the acceptor volume (mL), A the surface area (cm2), CD0 the concentration in the donor
chamber at start of experiment and DCA/Dt. the change in concentration in the acceptor compartment
over time (s).
The e✏ux ratio was determined according to:




To identify the uptake mechanism of the developed nanomicelles, Caco-2 cells were pre-incubated
with sodium azide (an ATP synthesis inhibitor, 1 µM), chlorpromazine (a clathrin blocker, 15 µM) and
indomethacin (a caveolin-dependent endocytosis inhibitor, 25 µM) for 30 min followed by the addition
of FITC-PNM or FITC-MNM 1:10 for 1 h and maintained at 4  C during the exposure. At the end of the
treatments, the amount of FITC was quantified on cellular lysate by HPLC analyses. In parallel, Caco-2
cells, grown on histological slides, were treated in the same conditions, fixed in 4% formaldehyde in
0.1 mol/L PBS pH 7.4, for 10 min and observed by fluorescence microscopy (Labophot-2 Nikon, Tokyo,
Japan). Ten photomicrographs were randomly taken for each sample, and fluorescence was measured
using ImageJ 1.33 image analysis software (http://rsb.info.nih.gov/ij).
RT-PCR
Total RNA was extracted from cell lysates using the Nucleo Spin® RNA kit (Macherey-Nagel,
Bethlehem, USA) according to manufacturer’s instructions. The P-gp gene expression in Caco-2 cells
was evaluated by RT-PCR analysis (Table 9), as previously described [54].
Table 9. Primers sequences.
Gene Primer Forward Primer Reverse Size
P-gp CAGAGGCTCTATGACCCCAC CAACTGGGCCCCTCTCTCTC 273
GAPDH CCCTCAAGGGCATCCTGGGCT GCAGGGACTCCCCAGCAGTGA 275
P-gp: P-glycoprotein; GAPDH: Glyceraldehyde 3-phosphate dehydrogenase.
3.2.11. Antioxidant Activity Studies
The antioxidant activity of SLM was assayed by the DPPH (1,1-diphenyl-2-picrylhydrazyl) test.
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SLM-PNM, SLM-MNM, and SLM solution were diluted with ethanol to obtain an equivalent
concentration of SLM, then 1 mL of each sample was added to an equal volume of DPPH ethanolic
solution (100 µM) and incubated in the dark for 20 min at room temperature. The antioxidant activity
of empty PNM and MNMwas also checked. The absorbance of the solutions was measured at 517 nm
against blank (ethanol) by a spectrophotometer [71].








where ADPPH is the control (absorbance of DPPH radicals without sample) and Asample is the absorbance
of radicals after reacting with the sample. The experiments were performed in triplicate.
3.2.12. Statistical Analysis
Data were analyzed by Kruskal-Wallis test and Dunn’s multiple comparisons test or by using
Mann Whitney test and expressed as mean ± standard error (SEM) or mean ± standard deviation (SD)
of three independent experiments. All analyses were carried out using GraphPad Prism 7.0 (GraphPad
Software, San Diego, CA, USA). P value of 0.05 was considered significant.
4. Conclusions
Since the clinical use of SLM is limited by its poor oral bioavailability, in this study the e↵ect of
Soluplus PNM and Soluplus/TPGS MNM on intestinal absorption and secretion was investigated. The
developed formulations showed small particle size (~50 nm), narrow PdI (~0.1), high encapsulation
e ciency (>92%) and did not interfere with the antioxidant capacity of the extract. PNM and MNM
increased the aqueous solubility of SLM by ~6 times and exhibited proper CMC for oral administration.
The stability during storage over three months and in simulated physiological conditions was assessed.
PAMPA demonstrated that PNM and MNM enhanced the passive di↵usion of SLM. Based on the
cellular results, nanomicelles have a significant inhibitory e↵ect on the P-gp-mediated e✏ux of SLM,
and MNM increased SLM permeability through Caco-2 cells’ monolayer compared to unformulated
extract and PNM. The obtained results encourage further studies on silymarin-loaded nanomicelles as
oral formulation.
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